{"id":6241,"date":"2025-04-03T15:30:20","date_gmt":"2025-04-03T12:30:20","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6241"},"modified":"2025-04-03T15:30:20","modified_gmt":"2025-04-03T12:30:20","slug":"the-role-of-maintaining-lower-ldl-c-level-during-statin-treatment-for-advanced-ckd-patients","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/the-role-of-maintaining-lower-ldl-c-level-during-statin-treatment-for-advanced-ckd-patients\/","title":{"rendered":"The Role of Maintaining Lower LDL-C Level During Statin Treatment for Advanced CKD Patients"},"content":{"rendered":"<div>\u00a0\u201cThe Role of Maintaining Lower LDL-C Level During Statin Treatment for Advanced CKD Patients\u201d<\/div>\n<div><\/div>\n<div>Summary of the Study:<\/div>\n<div>1. Background<\/div>\n<div><span> \u2022 A previous study in Taiwanese patients with stage 3 CKD showed that lowering LDL-c to &lt;70 mg\/dL or 70\u201399 mg\/dL reduced the risk of major adverse cardiac and cerebrovascular events (MACCE) and new-onset end-stage renal disease (ESRD) compared to LDL-c \u2265100 mg\/dL.<\/span><\/div>\n<div><span> \u2022 This study aimed to determine if similar benefits apply to patients with advanced CKD (stage 4\u20135).<\/span><\/div>\n<div><span> \u2022 No direct evidence from randomized controlled trials (RCTs) currently supports specific LDL-C targets for different CKD stages.<\/span><\/div>\n<div><span> \u2022 The impact of LDL-C lowering on cardiovascular and renal outcomes in advanced CKD (stage 4\u20135) remains unclear.<\/span><\/div>\n<div><span> \u2022 This cohort study suggests that statin users with LDL-C &lt;70 mg\/dL have relatively favorable 5-year cardiovascular (CV) and renal outcomes in advanced CKD patients.<\/span><\/div>\n<div><span> \u2022 Lower LDL-C levels may be beneficial for CV protection as CKD progresses, but further RCTs are needed.<\/span><\/div>\n<div><\/div>\n<div>2. Study Aim<\/div>\n<div><span> \u2022 To investigate whether maintaining a lower LDL-C level during statin treatment benefits patients with advanced CKD in terms of cardiovascular and renal outcomes.<\/span><\/div>\n<div><\/div>\n<div>3. Methods<\/div>\n<div><span> \u2022 Observational cohort study using data from patients with stage 4 CKD.<\/span><\/div>\n<div><span> \u2022 Patients categorized based on post-treatment LDL-C levels.<\/span><\/div>\n<div><span> \u2022 Outcomes compared between different LDL-C level groups.<\/span><\/div>\n<div><\/div>\n<div>4. Key Findings<\/div>\n<div><span> \u2022 Lower LDL-C levels (&lt;70 mg\/dL) were associated with:<\/span><\/div>\n<div><span> \u2022 Reduced cardiovascular risks, including MACCE and CV death.<\/span><\/div>\n<div><span> \u2022 Lower incidence of new-onset ESRD requiring dialysis.<\/span><\/div>\n<div><span> \u2022 No significant benefits observed for LDL-C levels between 70\u201399 mg\/dL.<\/span><\/div>\n<div><span> \u2022 No randomized trials confirm these findings, highlighting the need for further prospective studies.<\/span><\/div>\n<div><\/div>\n<div>5. Conclusion<\/div>\n<div><span> \u2022 The study suggests that maintaining LDL-C &lt;70 mg\/dL in statin-treated advanced CKD patients may provide cardiovascular and renal protection.<\/span><\/div>\n<div><span> \u2022 However, further RCTs are warranted to confirm these results.<\/span><\/div>\n<div><a href=\"https:\/\/www.atherosclerosis-journal.com\/article\/S0021-9150(24)01214-0\/fulltext\">https:\/\/www.atherosclerosis-journal.com\/article\/S0021-9150(24)01214-0\/fulltext<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0\u201cThe Role of Maintaining Lower LDL-C Level During Statin Treatment for Advanced CKD Patients\u201d Summary of the Study: 1. Background \u2022 A previous study in Taiwanese patients with stage 3 CKD showed that lowering LDL-c to &lt;70 mg\/dL or 70\u201399 mg\/dL reduced the risk of major adverse cardiac and cerebrovascular events (MACCE) and new-onset end-stage [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6241","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6241"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6241\/revisions"}],"predecessor-version":[{"id":6242,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6241\/revisions\/6242"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}